Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris
References (20)
- et al.
The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance in cardiovascular disorders
J Am Coll Cardiol
(1991) - et al.
Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase
Eur J Pharmacol
(1987) - et al.
Effect of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction
Am J Cardiol
(1990) - et al.
Elevated betathromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo
Am J Cardiol
(1981) - et al.
Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction
Am J Cardiol
(1982) - et al.
Circadian variation in platelet function in healthy volunteers
Am J Cardiol
(1992) - et al.
Inhibition of platelet function by organic nitrate vasodilators
Blood
(1980) Nitroglycerin and long acting nitrates
N Engl J Med
(1980)Nitrate therapy in stable angina
N Engl J Med
(1987)- et al.
Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor
Nature
(1987)
Cited by (31)
Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy
2016, International Journal of CardiologyCitation Excerpt :Whether or not this association is due to synergic anti-platelet potency requires randomized study of a large sample size, although our preliminary data seems important, despite lacking mechanistic explanation. Originally, nitrates are known to inhibit platelet function, which have been consistently shown in numerous studies, moreover, nitrates are commonly prescribed during and post-PCI mostly due to vasodilatation effects (e.g. [6–9,19]). Nitrates are known to activate guanylyl cyclase, and increase cellular cyclic guanosine monophosphates in smooth muscle and platelet [20].
Stable Ischemic Heart Disease
2016, Heart Failure ClinicsCitation Excerpt :NO also inhibits potassium channels to hyperpolarize muscle membranes and activates light chain phosphatase, both effecting relaxation, accounting for more vasodilatation. NO increases cGMP in platelets to reduce calcium and suppress platelet activation.23 In modest doses, nitrates reduce preload; in higher doses, they lower afterload.
Stable ischemic heart disease
2014, Cardiology Clinics2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease
2012, Journal of the American College of CardiologyThe Effects of Medications on Myocardial Perfusion
2008, Journal of the American College of CardiologyCitation Excerpt :The anti-ischemic effect of nitroglycerin might also be attributable to the redistribution of coronary flow from normal to ischemic myocardium through dilation of collateral vessels (10,11,18). Nitroglycerin may also preserve myocardial perfusion through the inhibition of platelet thrombus formation (19–22). Nitric oxide is capable of activating soluble guanylyl cyclase in platelets.
Acute and delayed antithrombotic effects of alcohol in humans
2001, American Journal of CardiologyCitation Excerpt :There is also excellent reproducibility (r = 0.95, p = 0.0001) between measurements performed 1 week apart.8,9 Repeat studies on the same morning in 11 patients taking a placebo agent showed no serial change in platelet thrombus size as assessed by this technique.11 Repeat studies in 17 stable patients at a mean of 2.1 and 7.6 months also showed no significant serial changes in platelet thrombus size.8,9